Scientific Research
Small doses of amber (succinic) acid were used to rejuvenate the hypothalamus by restoring its sensitivity.
V.M. Dilman, V.N. Anisimon, and M.N. Kondrashova. The influence of succinic (amber) and glutamic acids on the sensitivity of hypothalamo-gonadotropic system to inhibitory action of estrogens in old rats. Pharmacology and Toxicology 3, 540-551, 1976 (In Rus).
Scientific Research
In pre-clinical trials, succinic acid showed to improve menopausal changes and also exhibited very distinct signs of rejuvenation.
V.M. Dilman and V. N. Anisimov. Hypothalamic mechanisms of ageing and of specific age pathology—I. Sensitivity threshold of hypothalamo-pituitary complex to homeostatic stimuli in the reproductive system. Experimental gerontology 14.4 (1979): 161-173.
Scientific Research
Enerlit-Clima (equivalent of Amberen’s formulation) composition was developed. In preclinical trials, the supplement was shown to be safe (no acute or long-term toxicity) and to be effective for the alleviation of more than 12 menopausal symptoms.
Clinical Trial
Evaluation of Enerlit-Clima (equivalent of Amberen’s formulation) as a treatment for climacteric syndrome.
Study design: This randomized, placebo-controlled, double-blind, 3-week study involved 70 menopausal women.
Results: The results of the study demonstrated that Enerlit-Clima-based therapy helps alleviate many menopause symptoms when compared with the placebo group. No adverse side effects when taking Enerlit-Clima were registered.
Publication: E.I. Maevsky et al. A succinate-based composition reverses menopausal symptoms without sex hormone replacement therapy. Advances in gerontology= Uspekhi gerontologii/Rossiiskaia akademiia nauk, Gerontologicheskoe obshchestvo 21.2 (2008): 298-305.
Scientific Research
A 3-year-long observational clinical study on 245 women was conducted. Enerlit-Clima (equivalent of Amberen’s formulation) was shown to be safe and effective when it came to managing several menopausal symptoms.
Scientific Research
A U.S. patent was granted to Lunada Biomedical (currently Boigix), which had acquired the rights to Amberen’s proprietary formulation in 2006 for a method of synthesizing biologically active succinic acid (Patent No: US 8,546,611 B2. Date of patent: Oct. 1, 2013).
Clinical Trial
Study design: A 12-week randomized, placebo-controlled, double-blind, study with 102 women between 42 and 60 years of age with mild to moderate menopause symptoms.
Results: Women who took Amberen showed statistically significant improvements compared to the placebo group. The results of the safety evaluation showed Amberen to be a safe dietary supplement.
Publications: I.V. Kuznetsova et al. Effectiveness of alternative therapy in perimenopausal and postmenopausal women (in Russian). Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2016 5:126 - 33.
I.V. Kuznetsova et al. Effectiveness and safety of using a succinate-based dietary supplement for women in menopause. Medline.ru, 2016, Vol 17, Art. 3, p 24-45 (Mecine.ru/pdf)
Kuznetsova I.V, Uspenskaya Yu. B., Borisova N.I, Zhukova E.V., Berdnikova N.G., Gusak Yu. K Effectiveness and safety of using a succinate-based dietary supplement for women in menopause. Medline.ru, 2016, Vol 17, Art. 3, p 24-45 (Mecine.ru/pdf)
Presentations: Poster presentation at the 15th World Congress on Menopause. Effectiveness and safety of using Amberen supplementation in perimenopausal and postmenopausal women. Yu. Uspenskaya, I. Kuznetsova, N. Borisova, N. Berdnikova and U. Gusak
Clinical Trial
Study design: A 12-week randomized, placebo-controlled, double-blind study with 125 women between 42 and 60 years of age with mild to moderate menopause symptoms.
Results: Amberen was shown to be a safe and well-tolerated supplement with no adverse side effects. Compared to the placebo group, women who took Amberen reported significant improvements in many menopausal symptoms.
Publications: V.E. Radzinskii et al. Treatment of climacteric symptoms with an ammonium succinate-based dietary supplement: a randomized, double-blind, placebo-controlled trial. (2016) Gynecological Endocrinology, 32:sup2, 64-68, DOI: 10.1080/09513590.2016.1232686
Presentations: Oral presentation of the 2015/2016 Amberen clinical trial results By Y.B. Uspenskaya: International Menopause Society, 25th World Congress on Controversies in Obstetrics, Gynecology and Infertility, Amsterdam, Netherlands, November 10-13, 2016.
Research
Data from two trials were pooled in order to continue to evaluate and further confirm Amberen’s efficacy. The analysis of the larger data set showed that Amberen relieves 16 menopausal symptoms.
V.E. Radzinsky et al. Succinate-Based Dietary Supplement for Menopausal Symptoms: A Pooled Analysis of Two Identical Randomized, Double-Blind, Placebo-Controlled Clinical Trials. Obstetrics and Gynecology International, vol. 2019, Article ID 1572196, 9 pages, 2019. https://doi.org/10.1155/2019/1572196.
